CTIS2023-509814-12-00
Active, not recruiting
Phase 1
OPTIMISE OPTIMIzation of treatment SElection and follow up in oligometastatic colorectal cancer – a ctDNA guided phase II randomized approach
Region Midtjylland0 sites350 target enrollmentNovember 23, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Colorectal cancer with metastasis
- Sponsor
- Region Midtjylland
- Enrollment
- 350
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Radical intended treatment for metastatic spread from colorectal cancer, by resection, RFA, SBRT (or other experimental local treatment options) not including cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), No evidence of further disease based on pre\-treatment work\-up according to standard of care, Age at least 18 years, ECOG performance status 0\-2, Clinically eligible for adjuvant triple CT at investigators decision, Adequate bone marrow, liver and renal function allowing systemic chemotherapy (absolute neutrophil count \=1\.5x10^9/l and thrombocytes \= 100x10^9/l. Bilirubin \= 1\.5 x upper normal value and alanine aminotransferase \= 3 x upper normal value, and calculated or measured renal glomerular filtration rate at least 30 mL/min), Anticonception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject’s male partner or hormonal contraceptive are acceptable, Written and verbally informed consent
Exclusion Criteria
- •Neuropathy National Cancer Institute Common Terminology Criteria for Adverse Events (NCI\-CTCAE) grade \> 1, Other malignant tumour within 5 years except non\-melanoma skin cancer or carcinoma in situ cervicis uteri, Pregnant (positive pregnancy test) or breast feeding women, Intolerance or allergy to 5FU, leucovorin, oxaliplatin, irinotecan or capecitabin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
OPTIMISE: A study investigating if analysis of cancer DNA in blood can be used to guide adjuvant treatment in patients with advanced colorectal cancerMedDRA version: 21.0Level: PTClassification code 10010035Term: Colorectal cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-004524-41-DKAarhus University Hospital/Karen-Lise Garm Spindler350
Completed
Not Applicable
The optimal treatment strategy for complex appendicitis in the pediatric populatio<p>Acute complex appendicitis</p>10017966NL-OMON26201Amsterdam UMC1,308
Not yet recruiting
Phase 1
The efficacy and safety of chinese herbal medicine Shen-Qi Hua-Yu formula in patients with diabetic lower extremity artery disease: a multi-centre, randomized, double-blind, placebo-controlled trialDiabetic Lower Extremity Artery DiseaseITMCTR1900002645Hospital of Chengdu University of Traditional Chinese Medicine
Recruiting
Phase 1
Optimization Research of Clinical treatment Scheme of traditional Chinese Medicine for multiple SclerosisITMCTR2100004480Beijing Tiantan Hospital Affiliated to Capital Medical University
Completed
Not Applicable
Improving treatment selection for head and neck cancers and dysplasiaHead and neck cancerCancerMalignant neoplasm of head and neckISRCTN07132994niversity Hospitals Coventry & Warwick (UK)1,400